Wei Shuqin, Wo Bi Lan, Qi Hui-Ping, Xu Hairong, Luo Zhong-Cheng, Roy Chantal, Fraser William D
Département d'Obstétrique-Gynécologie, Université de Montréal, Hôpital, Canada.
Cochrane Database Syst Rev. 2012 Sep 12;9(9):CD006794. doi: 10.1002/14651858.CD006794.pub3.
Caesarean section rates are over 20% in many developed countries. The main diagnosis contributing to the high rate in nulliparae is dystocia or prolonged labour. The present review assesses the effects of a policy of early amniotomy with early oxytocin administration for the prevention of, or the therapy for, delay in labour progress.
To estimate the effects of early augmentation with amniotomy and oxytocin for prevention of, or therapy for, delay in labour progress on the caesarean birth rate and on indicators of maternal and neonatal morbidity.
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (15 February 2012), MEDLINE (1966 to 15 February 2012), EMBASE (1980 to 15 February 2012), CINAHL (1982 to 15 February 2012), MIDIRS (1985 to February 2012) and contacted authors for data from unpublished trials.
Randomized and quasi-randomized controlled trials that compared oxytocin and amniotomy with expectant management.
Three review authors extracted data independently. We stratified the analyses into 'Prevention Trials' and 'Therapy Trials' according to the status of the woman at the time of randomization. Participants in the 'Prevention Trials' were unselected women, without slow progress in labour, who were randomized to a policy of early augmentation or to routine care. In 'Treatment Trials' women were eligible if they had an established delay in labour progress.
For this update, we have included a further two new clinical trials. This updated review includes 14 trials, randomizing a total of 8033 women. The unstratified analysis found early intervention with amniotomy and oxytocin to be associated with a modest reduction in the risk of caesarean section; however, the confidence interval (CI) included the null effect (risk ratio (RR) 0.89; 95% CI 0.79 to 1.01; 14 trials; 8033 women). In prevention trials, early augmentation was associated with a modest reduction in the number of caesarean births (RR 0.87; 95% CI 0.77 to 0.99; 11 trials; 7753). A policy of early amniotomy and early oxytocin was associated with a shortened duration of labour (average mean difference (MD) - 1.28 hours; 95% CI -1.97 to -0.59; eight trials; 4816 women). Sensitivity analyses excluding four trials with a full package of active management did not substantially affect the point estimate for risk of caesarean section (RR 0.87; 95% CI 0.73 to 1.05; 10 trials; 5165 women). We found no other significant effects for the other indicators of maternal or neonatal morbidity.
AUTHORS' CONCLUSIONS: In prevention trials, early intervention with amniotomy and oxytocin appears to be associated with a modest reduction in the rate of caesarean section over standard care.
在许多发达国家,剖宫产率超过20%。导致初产妇剖宫产率高的主要诊断是难产或产程延长。本综述评估早期人工破膜联合早期使用缩宫素预防或治疗产程进展延迟的政策效果。
评估早期人工破膜联合缩宫素预防或治疗产程进展延迟对剖宫产率以及孕产妇和新生儿发病率指标的影响。
我们检索了Cochrane妊娠与分娩组试验注册库(2012年2月15日)、MEDLINE(1966年至2012年2月15日)、EMBASE(1980年至2012年2月15日)、CINAHL(1982年至2012年2月15日)、MIDIRS(1985年至2012年2月),并联系作者获取未发表试验的数据。
比较缩宫素和人工破膜与期待治疗的随机和半随机对照试验。
三位综述作者独立提取数据。我们根据随机分组时女性的状态将分析分为“预防试验”和“治疗试验”。“预防试验”的参与者是未经过挑选、产程没有进展缓慢的女性,她们被随机分配接受早期引产政策或常规护理。在“治疗试验”中,如果女性产程进展已确定延迟,则符合条件。
对于本次更新,我们又纳入了两项新的临床试验。本次更新后的综述包括14项试验,共随机分配了8033名女性。未分层分析发现,早期人工破膜联合缩宫素干预与剖宫产风险适度降低相关;然而,置信区间(CI)包含无效效应(风险比(RR)0.89;95%CI 0.79至1.01;14项试验;8033名女性)。在预防试验中,早期引产与剖宫产数量适度减少相关(RR 0.87;95%CI 0.77至0.99;11项试验;7753名女性)。早期人工破膜和早期缩宫素政策与产程缩短相关(平均差值(MD)-1.28小时;95%CI -1.97至-0.59;8项试验;4816名女性)。排除四项采用全套积极管理措施的试验后的敏感性分析,对剖宫产风险的点估计值没有实质性影响(RR 0.87;95%CI 0.73至1.05;10项试验;5165名女性)。我们未发现对其他孕产妇或新生儿发病率指标有其他显著影响。
在预防试验中,早期人工破膜联合缩宫素干预似乎比标准护理能适度降低剖宫产率。